Molecular-cytogenetic monitoring of different regimens of treatment


Cite item

Full Text

Abstract

Aim. To conduct molecular-cytogenetic monitoring of bone marrow cells in different regimens of chronic myeloid leukemia (CML) treatment.
Material and methods. A total of 651 samples of bone marrow from 319 CML patients were studied. 229patients receivedpolychemotherapy and 90patients - interferon-alpha. Primary examination and monitoring of the treatment efficacy were performed using G-differential chromosome staining. Fluorescent in situ hybridization (FISH) was made in 75% cases.
Results. Interferon therapy resulted in a significant increase in the number of complete and significant cytogenetic responses. With aggravation of the disease the above responses occurred less frequently while minor and no response are encountered more often. Treatment with interferon-alpha in combination with chemotherapy is much more effective than monotherapy with interferon. Conclusion. G-differential chromosome staining karyotypes metaphases and detects clonal chromosome restructuring. Molecular-cytogenetic methods study chromosome restructuring at DNA level. FISH detects chimeric gene bcr/abl in cases when Ph-chromosome is not detectable by standard cytogenetic methods.

References

  1. Talpaz M., Kantarjian H. M., McCredie К. В. et al. Clinical investigation of human alpha-interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280-1288.
  2. Туркина А. Г., Хорошко Н. Д., Полонская Э. Н. и др. Лечение хронической стадии Ph'-положительного хронического миелолейкоза интерфероном-альфа 2Ь по протоколу ХМЛ МИГ-97. Гематол. и трансфузиол. 1999; 44 (4): 36- 39.
  3. Хорошко Н. Д., Туркина А. Г., Журавлев В. С. и др. Терапия больных в ранней хронической фазе Ph-положительного хронического миелолейкоза взрослых препаратами интерферона а-2Ь (первое сообщение по результатам кооперированного исследования по протоколу ХМЛ МИГ-97). Тер. арх. 1999; 7:42-47.
  4. Sokal J. Е., Сох Е. В., Baccarani M. et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-795.
  5. Kobzev Y. N., Domracheva E. V., Zakharova A. et al. Fluorescence in situ hybridization studies of interphase nuclei for assessing response to therapy in patients with chronic myeloid leukemia. Cancer Genet. Cytogenet. 1998; 106: 128-134.
  6. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971; 7731: 971-972.
  7. Юнис Дж. Дж. Клиническая значимость метода задержки конденсации хромосом при изучении острых лейкозов и неходжкинских лимфом. В кн.: Современная гематология и онкология. М.: Медицина; 1987. 351-390.
  8. Pinkel D., Straume Т., Gray J. M. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc. Nat. Acad. Sci. USA 1986; 83: 2934-2935.
  9. Lazaridou A., Chase A., Melo J. et al. Lack of reciprocal translocation in BCR/ABL positive Ph-negative chronic myeloid leukaemia. Leukemia 1994; 8: 454-457.
  10. Kantarjian H., Deisseroth A., Kuryock R. et al. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691 - 703.
  11. Alimena G., Morra E., Lazzarino M. et al. Interferon alfa 2b as a therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermitent or daily administration. Blood 1988; 72: 642-647.
  12. Freud M., Hild F., Grote-Metke A. et al. Combination of chemotherapy and Interferon Alfa-2b in the treatment of chronic myelogenous leukemia. Semin. Hematol. 1993; 30 (3): 11-13.
  13. Хорошко Н. Д., Туркина А. Г., Кузнецов С. В, и др. Хронический миелолейкоз - успехи современного лечения и перспективы. Гематол. и трансфузиол. 2001; 46 (4): 3-8.
  14. Niederle К., Шоке О., Osieka R. et al. Treatment of chronic and acute phase chronic myelogenous leukemia with interferon. Blood 1988; 72: 119-128.
  15. Ozer H., George S. L., Schiffer С. A. et al. Prolonged subcutaneous administration of recombinant a 2-b-interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group В Study 8583. Blood 1993; 82 (10): 2975-2984.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies